Clover Announces Positive Phase 2/3 Results in Adolescents for its COVID-19 Vaccine

Clover Announces Positive Phase 2/3 Results in Adolescents for its COVID-19 Vaccine

Source: 
BioSpace
snippet: 

SCB-2019 (CpG 1018/Alum) elicited approximately 2-fold higher neutralizing antibody titers in adolescents (aged 12 to 17 years) compared to young adults (aged 18 to 25 years)